GALLERY

Principales Publications Scientifiques depuis 2018

—

Geoffroy PA, Lejoyeux M, Rolland B.
Management of insomnia in alcohol use disorder.

Expert Opin Pharmacother. 2020; 3:1-10. doi: 10.1080/14656566.2019.1705279.

Chappuy M, Boulanger A, Nourredine M, Fourneret P, Rolland B.
Disparate regulatory status of methylphenidate for adults with ADHD across Europe.

Lancet Psychiatry. 2020; 7(1):e1-e2. doi: 10.1016/S2215-0366(19)30482-1.

Meyrel M, Rolland B, Geoffroy PA.
Alterations in circadian rhythms following alcohol use: A systematic review.

Prog Neuropsychopharmacol Biol Psychiatry. 2019; doi: 10.1016/j.pnpbp.2019.109831.

Rolland B, Simon N, Franchitto N, Aubin HJ.
France Grants an Approval to Baclofen for Alcohol Dependence.

Alcohol Alcohol. 2019; doi: 10.1093/alcalc/agz082.

Pignon B, Sescousse G, Amad A, Benradia I, Vaiva G, Thomas P, Geoffroy PA, Roelandt JL, Rolland B.
Alcohol Use Disorder Is Differently Associated With Psychotic Symptoms According To Underlying Psychiatric Disorders: A General Population Study.

Alcohol Alcohol. 2019; doi: 10.1093/alcalc/agz077

Barre T, Marcellin F, Di Beo V, Delorme J, Rojas Rojas T, Mathurin P, Protopopescu C, Bailly F, Coste M, Authier N, Carrieri MP, Rolland B.
Untreated alcohol use disorder in people who inject drugs (PWID) in France: a major barrier to HCV treatment uptake (the ANRS-FANTASIO study).

Addiction. 2019; doi: 10.1111/add.14820.

Li Y, Wang Z, Boileau I, Dreher JC, Gelskov S, Genauck A, Joutsa J, Kaasinen V, Perales JC, Romanczuk-Seiferth N, Ruiz de Lara CM, Siebner HR, van Holst RJ, van Timmeren T, Sescousse G. 
Altered orbitofrontal sulcogyral patterns in gambling disorder: a multicenter study.

Transl Psychiatry. 2019; 9(1):186.

Vorspan F, Hjelmström P, Simon N, Benyamina A, Dervaux A, Brousse G, Jamain T, Kosim M, Rolland B. 
What place for prolonged-release buprenorphine depot formulation Buvidal® in the treatment arsenal of opioid dependence? Insights from the French experience on buprenorphine.

Expert Opin Drug Deliv. 2019. doi: 10.1080/17425247.2019.1649252.

Carton L, Auger F, Kyheng M, Pétrault M, Durieux N, Allorge D, Cottencin O, Jardri R, Bordet R, Rolland B. 
Dose-dependent metabolite changes after ethanol intoxication in rat prefrontal cortex using in vivo magnetic resonance spectroscopy.

Sci Rep. 2019; 9(1):10682.

De Ternay J, Naassila M, Nourredine M, Louvet A, Bailly F, Sescousse G, Maurage P, Cottencin O, Carrieri PM, Rolland B.
Therapeutic Prospects of Cannabidiol for Alcohol Use Disorder and Alcohol-Related Damages on the Liver and the Brain.

Front Pharmacol. 2019; 10:627. doi: 10.3389/fphar.2019.00627.

Mas-Herrero E, Sescousse G, Cools R, Marco-Pallarés J.
The contribution of striatal pseudo-reward prediction errors to value-based decision-making. 
Neuroimage. 2019 Jun;193:67-74.

Groefsema MM, Engels RCME, Voon V, Schellekens AFA, Luijten M, Sescousse G.
Brain responses to anticipating and receiving beer: Comparing light, at-risk, and dependent alcohol users.
Addict Biol. 2019; e12766. doi: 10.1111/adb.12766.

Rojas Rojas T, Di Beo V, Delorme J, Barre T, Mathurin P, Protopopescu C, Bailly F, Coste M, Authier N, Carrieri MP, Rolland B, Marcellin F.  
Lower HCV treatment uptake in women who have received opioid agonist therapy before and during the DAA era: The ANRS FANTASIO project. 
Int J Drug Policy. 2019; pii: S0955-3959(19)30135-5.

Rolland B, Dricot L, Creupelandt C, Maurage P, De Timary P. 
Respective influence of current alcohol consumption and duration of heavy drinking on brain morphological alterations in alcohol use disorder. 

Addict Biol. 2019 Apr 9:e12751. doi: 10.1111/adb.12751.

Rolland B, D'Hondt F, Montègue S, Brion M, Peyron E, D'Aviau de Ternay J, de Timary P, Nourredine M, Maurage P. 

A Patient-Tailored Evidence-Based Approach for Developing Early Neuropsychological Training Programs in Addiction Settings.

Neuropsychol Rev. 2019; 29(1):103-115.

Lenglard F, Berger-Vergiat A, Ragonnet D, Duvernay N, Lack P, Poulet E, Zoulim F, Chappuy M.

Retour d'expérience de deux CSAPA et enquête nationale sur la naloxone intranasale (Nalscue®) dans la prévention des overdoses aux opioïdes. 

Thérapie. 2019; 74(4):477-486.

Agabio R, Sinclair JM, Addolorato G, ..., Rolland B, Stafford A, Thompson A, van den Brink W, de Beaurepaire R, Leggio L. 
Baclofen for the treatment of alcohol use disorder: the Cagliari Statement. 
Lancet Psychiatry. 2018; 5(12):957-960.

D'Hondt F, Lescut C, Maurage P, Menard O, Gibour B, Cottencin O, Montègue S, Jardri R, Rolland B. 
Psychiatric comorbidities associated with a positive screening using the Montreal Cognitive Assessment (MoCA) test in subjects with severe alcohol use disorder. 
Drug Alcohol Depend. 2018; 191:266-269.

Simon N, Moirand R, Dematteis M, Bordet R, Deplanque D, Rolland B.
Full-Profile Pharmacokinetic Study of High Dose Baclofen in Subjects With Alcohol Use Disorder.

Front Psychiatry. 2018; 9:385.

Rolland B, Simon N, Franchitto N.
Safety Challenges of Using High Dose Baclofen for Alcohol Use Disorder: A Focused Review.
Front Psychiatry. 2018; 9:367.

Carton L, Pignon B, Baguet A, Benradia I, Roelandt JL, Vaiva G, Thomas P, Amad A, De Timary P, Naassila M, Geoffroy PA, Rolland B.
Influence of comorbid alcohol use disorders on the clinical patterns of major depressive disorder: A general population-based study.

Drug Alcohol Depend. 2018; 187:40-47.

​